相似文献
1
Emerging roles of ATF2 and the dynamic AP1 network in cancer.
Nat Rev Cancer. 2010 Jan;10(1):65-76. doi: 10.1038/nrc2681.
2
[Ap1-like cis-elements in 5'-regulatory region of human apolipoprotein A-I gene].
Mol Biol (Mosk). 2008 Mar-Apr;42(2):295-305.
3
Transient receptor potential melastatin-3 (TRPM3)-induced activation of AP-1 requires Ca2+ ions and the transcription factors c-Jun, ATF2, and ternary complex factor.
Mol Pharmacol. 2015 Apr;87(4):617-28. doi: 10.1124/mol.114.095695. Epub 2015 Jan 9.
4
Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization.
EMBO J. 2006 Mar 8;25(5):1058-69. doi: 10.1038/sj.emboj.7601020. Epub 2006 Mar 2.
5
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
Blood. 2016 Apr 7;127(14):1780-9. doi: 10.1182/blood-2015-07-655647. Epub 2016 Jan 8.
6
Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.
Mol Endocrinol. 2008 Aug;22(8):1767-80. doi: 10.1210/me.2007-0574. Epub 2008 Jun 5.
7
Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kappaB oncogenesis.
Oncogene. 2010 Sep 2;29(35):4925-37. doi: 10.1038/onc.2010.239. Epub 2010 Jun 21.
8
Opposing roles for ATF2 and c-Fos in c-Jun-mediated neuronal apoptosis.
Mol Cell Biol. 2009 May;29(9):2431-42. doi: 10.1128/MCB.01344-08. Epub 2009 Mar 2.
9
Phosphorylation of ATF2 and interaction with NFY induces c-Jun in the gonadotrope.
Mol Cell Endocrinol. 2013 Jan 30;365(2):316-26. doi: 10.1016/j.mce.2012.11.012. Epub 2012 Nov 20.
10
AP-1 activated by toll-like receptors regulates expression of IL-23 p19.
J Biol Chem. 2009 Sep 4;284(36):24006-16. doi: 10.1074/jbc.M109.025528. Epub 2009 Jul 10.
引用本文的文献
1
ATF2-mediated Transcriptional Activation of USP4 Stabilizes KMT2A Protein and Promotes Trophoblast Dysfunction.
Reprod Sci. 2025 Aug 13. doi: 10.1007/s43032-025-01938-z.
2
The role of ubiquitination and deubiquitination in urological tumours.
Front Pharmacol. 2025 Jul 23;16:1532878. doi: 10.3389/fphar.2025.1532878. eCollection 2025.
3
The AP-1 factor JUNB correlates with poor survival of patients with esophageal adenocarcinoma.
Sci Rep. 2025 Jul 23;15(1):26790. doi: 10.1038/s41598-025-07393-9.
4
Challenges and opportunities for the diverse substrates of SPOP E3 ubiquitin ligase in cancer.
Theranostics. 2025 May 8;15(13):6111-6145. doi: 10.7150/thno.113356. eCollection 2025.
5
Jund orchestrates -regulatory element dynamics to facilitate endothelial-to-hematopoietic transition.
Proc Natl Acad Sci U S A. 2025 Jun 10;122(23):e2426714122. doi: 10.1073/pnas.2426714122. Epub 2025 Jun 5.
6
Identification of a novel immune checkpoint-related gene signature predicts prognosis and immunotherapy in breast cancer and experiment verification.
Sci Rep. 2024 Dec 28;14(1):31065. doi: 10.1038/s41598-024-82266-1.
7
Identification of key genes to predict response to chemoradiotherapy and prognosis in esophageal squamous cell carcinoma.
Front Mol Biosci. 2024 Nov 20;11:1512715. doi: 10.3389/fmolb.2024.1512715. eCollection 2024.
8
Novel PROTAC probes targeting FOSL1 degradation to eliminate head and neck squamous cell carcinoma cancer stem cells.
Bioorg Chem. 2024 Oct;151:107613. doi: 10.1016/j.bioorg.2024.107613. Epub 2024 Jul 9.
9
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
Mol Cancer. 2024 May 29;23(1):114. doi: 10.1186/s12943-024-02022-x.
10
miRNAs in radiotherapy resistance of cancer; a comprehensive review.
Cell Biochem Biophys. 2024 Sep;82(3):1665-1679. doi: 10.1007/s12013-024-01329-2. Epub 2024 May 28.
本文引用的文献
1
Inflammation and cancer: how friendly is the relationship for cancer patients?
Curr Opin Pharmacol. 2009 Aug;9(4):351-69. doi: 10.1016/j.coph.2009.06.020. Epub 2009 Aug 6.
2
JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.
Cancer Cell. 2009 Apr 7;15(4):341-52. doi: 10.1016/j.ccr.2009.02.016.
3
Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas.
Anticancer Res. 2009 Jan;29(1):183-9.
4
Concordant overexpression of phosphorylated ATF2 and STAT3 in extramammary Paget's disease.
J Cutan Pathol. 2009 Apr;36(4):402-8. doi: 10.1111/j.1600-0560.2008.01076.x.
5
Opposing roles for ATF2 and c-Fos in c-Jun-mediated neuronal apoptosis.
Mol Cell Biol. 2009 May;29(9):2431-42. doi: 10.1128/MCB.01344-08. Epub 2009 Mar 2.
6
Phosphorylation of Activation Transcription Factor-2 at Serine 121 by Protein Kinase C Controls c-Jun-mediated Activation of Transcription.
J Biol Chem. 2009 Mar 27;284(13):8567-81. doi: 10.1074/jbc.M808719200. Epub 2009 Jan 28.
7
Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer.
Eur J Cancer. 2009 Mar;45(5):866-73. doi: 10.1016/j.ejca.2008.12.006. Epub 2009 Jan 10.
8
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.
Cancer Res. 2008 Dec 1;68(23):9663-70. doi: 10.1158/0008-5472.CAN-08-2229.
9
C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.
Br J Cancer. 2008 Oct 21;99(8):1269-75. doi: 10.1038/sj.bjc.6604650.
10
An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation.
Oncogene. 2009 Jan 8;28(1):73-84. doi: 10.1038/onc.2008.370. Epub 2008 Oct 13.
Zotero 插件